Emergent BioSolutions grants 100,111 RSUs to SVP

Lowry Simon C reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Lowry Simon C reported acquisition or exercise transactions in this Form 4 filing.

Emergent BioSolutions Inc. granted SVP, R&D, CMO Simon C. Lowry 100,111 shares of common stock in the form of restricted stock units. The award was approved by the Compensation Committee on March 2, 2026 and became effective after stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming continued service. Each unit entitles Lowry to receive one share of common stock, bringing his direct holdings to 177,914 shares after the grant.

Insider Trade Summary

Grant/Award: 100,111 shares

Grant/Award 1 txn

Insider Lowry Simon C

Role SVP, R&D, CMO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	100,111	$0.00	$0.00

Holdings After Transaction: Common Stock — 177,914 shares (Direct)

Footnotes (2)

1. F1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
2. F2. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Key Figures

RSUs granted: 100,111 shares Holdings after grant: 177,914 shares Committee approval date: March 2, 2026 +2 more

5 metrics

RSUs granted 100,111 shares Restricted stock units awarded to Simon C. Lowry

Holdings after grant 177,914 shares Total direct common stock holdings following transaction

Committee approval date March 2, 2026 Compensation Committee approval of RSU grant

Stockholder approval date April 29, 2026 Stockholders approved Amended Stock Incentive Plan

Vesting schedule Three annual installments RSUs vest annually beginning on approval anniversary

Key Terms

restricted stock units, Amended Stock Incentive Plan, Compensation Committee, vest in three annual installments

4 terms

restricted stock units financial

"Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended Stock Incentive Plan financial

"subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan")."

Compensation Committee financial

"The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

vest in three annual installments financial

"These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval,"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Emergent BioSolutions (EBS) disclose in this Form 4 for Simon C. Lowry?

Emergent BioSolutions reported that SVP, R&D, CMO Simon C. Lowry received 100,111 restricted stock units. These awards are part of his equity compensation and increase his direct holdings to 177,914 common shares in the company.

How many restricted stock units did Simon C. Lowry receive from Emergent BioSolutions (EBS)?

Simon C. Lowry received 100,111 restricted stock units of Emergent BioSolutions common stock. Each unit represents the right to one share upon vesting, subject to the terms and adjustments outlined in the applicable grant agreement.

How and when do Simon C. Lowry’s Emergent BioSolutions (EBS) RSUs vest?

The restricted stock units vest in three annual installments, starting on the anniversary of the approval date. Vesting depends on Lowry’s continued service with Emergent BioSolutions, aligning his compensation with longer-term employment and company performance.

What approvals were required for Simon C. Lowry’s RSU grant at Emergent BioSolutions (EBS)?

The RSU grant was approved by the Compensation Committee on March 2, 2026, subject to stockholder approval of the Amended Stock Incentive Plan. Stockholders subsequently approved the plan on April 29, 2026, allowing the grant to take effect.

What is Simon C. Lowry’s total Emergent BioSolutions (EBS) share ownership after this RSU grant?

Following the RSU grant, Simon C. Lowry directly holds 177,914 shares of Emergent BioSolutions common stock. This figure includes the newly awarded restricted stock units reported in the Form 4 insider transaction filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lowry Simon C

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MARYLAND 20879

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, R&D, CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026	04/29/2026(1)	A		100,111(2)	A	$0	177,914	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

2. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)